Supriya Lifescience Limited (IN:SUPRIYA)
:SUPRIYA
Want to see IN:SUPRIYA full AI Analyst Report?
Top Page
Supriya Lifescience Limited
(SUPRIYA)
Select Model
Select Model
Rating:80Outperform
Price Target:
₹811.00
▲(7.99% Upside)
Action:UpgradedDate:04/28/26
The score is primarily supported by strong financial performance (solid growth, expanding profitability, and a de-risked balance sheet) and favorable technical momentum (price above major moving averages with positive MACD). This is tempered by a relatively rich valuation (P/E ~30 and minimal dividend yield).
Positive Factors
Scale and Revenue Growth
Sustained revenue doubling over five years indicates durable demand and successful market penetration in APIs. Larger scale supports fixed-cost absorption, enables broader customer coverage and product development, and strengthens negotiating power with suppliers and buyers over the next 2–6 months and beyond.
Negative Factors
Free Cash Flow Volatility
FCF only recently turned positive after multi-year negatives, signalling prior cash conversion issues. Persistent volatility in FCF can constrain reinvestment, dividend capacity and buffer against shocks, making funding needs and timing less predictable.
Read all positive and negative factors
Positive Factors
Negative Factors
Scale and Revenue Growth
Sustained revenue doubling over five years indicates durable demand and successful market penetration in APIs. Larger scale supports fixed-cost absorption, enables broader customer coverage and product development, and strengthens negotiating power with suppliers and buyers over the next 2–6 months and beyond.
Read all positive factors
Supriya Lifescience Limited (SUPRIYA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹56.74B
Dividend Yield0.13%
Average Volume (3M)18.01K
Price to Earnings (P/E)30.4
Beta (1Y)1.21
Revenue Growth9.68%
EPS Growth6.17%
CountryIN
Employees448
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)6.20
Shares Outstanding80,482,800
10 Day Avg. Volume18,341
30 Day Avg. Volume18,009
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)5.91
Price to Sales (P/S)8.46
P/FCF Ratio578.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)30.65
Revenue Forecast (FY)₹10.17B
Supriya Lifescience Limited Business Overview & Revenue Model
Company Description
Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti...
How the Company Makes Money
Supriya Lifescience makes money primarily by manufacturing and selling active pharmaceutical ingredients (APIs) in bulk to pharmaceutical companies that use these ingredients to produce finished formulations (e.g., tablets, capsules, injectables)....
Supriya Lifescience Limited Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
85
Very Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.15B | 6.96B | 5.70B | 4.51B | 5.19B | 3.85B |
| Gross Profit | 4.83B | 3.84B | 2.80B | 2.80B | 2.89B | 2.34B |
| EBITDA | 2.68B | 2.71B | 1.84B | 1.37B | 2.22B | 1.77B |
| Net Income | 1.82B | 1.88B | 1.19B | 898.57M | 1.52B | 1.24B |
Balance Sheet | ||||||
| Total Assets | 12.03B | 11.12B | 9.21B | 8.20B | 7.35B | 4.46B |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 791.54M | 749.56M | 1.58B | 2.25B | 864.27M |
| Total Debt | 52.32M | 53.80M | 54.88M | 224.68M | 274.15M | 721.94M |
| Total Liabilities | 1.21B | 1.16B | 1.06B | 1.21B | 1.19B | 1.77B |
| Stockholders Equity | 10.82B | 9.97B | 8.15B | 6.99B | 6.16B | 2.69B |
Cash Flow | ||||||
| Free Cash Flow | 133.16M | 101.89M | -323.48M | -422.13M | -111.03M | 316.89M |
| Operating Cash Flow | 555.65M | 1.73B | 1.13B | 661.87M | 488.01M | 799.30M |
| Investing Cash Flow | -304.29M | -1.62B | -1.74B | -1.33B | -598.22M | -468.01M |
| Financing Cash Flow | -10.75M | -65.47M | -223.59M | -97.77M | 1.50B | -145.16M |
Supriya Lifescience Limited Technical Analysis
Positive
751.00
Price Trends
633.03
Positive
685.46
Negative
695.21
Negative
Market Momentum
4.69
Negative
59.29
Neutral
68.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUPRIYA, the sentiment is Positive. The current price of 751 is above the 20-day moving average (MA) of 604.14, above the 50-day MA of 633.03, and above the 200-day MA of 695.21, indicating a neutral trend. The MACD of 4.69 indicates Negative momentum. The RSI at 59.29 is Neutral, neither overbought nor oversold. The STOCH value of 68.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SUPRIYA.
Supriya Lifescience Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ₹56.74B | 30.45 | ― | 0.13% | 9.68% | 6.17% | |
57 Neutral | ₹34.81B | 23.17 | ― | 0.24% | 8.22% | 33.26% | |
57 Neutral | ₹29.38B | 67.80 | ― | 0.03% | 9.88% | -40.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹55.79B | -9.14 | ― | ― | -6.77% | -87.71% | |
41 Neutral | ₹47.67B | -13.56 | ― | ― | -13.08% | 31.05% |
* Healthcare Sector Average
IN:SUPRIYA
Supriya Lifescience Limited
704.50
33.67
5.02%
IN:AARTIDRUGS
Aarti Drugs Limited
380.50
31.02
8.88%
IN:GUFICBIO
Gufic Biosciences Limited
289.60
-84.80
-22.65%
IN:SPARC
Sun Pharma Advanced Research Co. Ltd.
146.80
-1.85
-1.24%
IN:SUVEN
Suven Life Sciences Limited
218.45
87.25
66.50%
Supriya Lifescience Limited Corporate Events
Supriya Lifescience Publishes Postal Ballot Notice in Newspapers
Mar 11, 2026
Supriya Lifescience Limited notified the stock exchanges that it has published a notice of postal ballot in major newspapers as part of its regulatory obligations. The advertisement appeared on 11 March 2026 in the Financial Express and Loksatta, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.